Clinical Trial Update: A Phase 1/2a Study to Evaluate Single Intraarticular Injections of 3 Dose Levels of SYN321 and Placebo in Patients With Symptomatic Knee Osteoarthritis [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2a study evaluated three intraarticular dose levels of SYN321 versus placebo for symptomatic knee osteoarthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis of the Knee

Drugs mentioned

• SYN321 (SYN321)

Snippet

Sponsor: Synartro AB | Conditions: Osteoarthritis of Knee | Phase 1, Phase 2 | Status: COMPLETED